Influence of growth hormone therapy on germinoma survivors

• Published in: Pituitary Vol. 25; no. 6; pp. 854 - 860
• Main Authors: Kinoshita, Yasuyuki, Yamasaki, Fumiyuki, Taguchi, Akira, Takayasu, Takeshi, Yonezawa, Ushio, Tominaga, Atsushi, Arita, Kazunori, Okada, Satoshi, Horie, Nobutaka, Sugiyama, Kazuhiko
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.12.2022; Springer Nature B.V
• Subjects: Biopsy; Endocrine therapy; Endocrinology; Epidemiology; Growth hormones; Human Physiology; Magnetic resonance imaging; Medical records; Medicine; Medicine & Public Health; Neoplasia; Patients; Pituitary (posterior); Survival; Tumors; Recurrence; Second neoplasm; Cancer survivor; Germinoma; Growth hormone therapy; Growth hormone deficiency
• ISSN: 1386-341X; 1573-7403
• DOI: 10.1007/s11102-022-01273-5

Purpose Due to the effectiveness of growth hormone therapy (GHT), the number of cancer survivors receiving GHT has increased. Previous studies had indicated that GHT was not associated with the increasing risks of tumor recurrence and development with second neoplasm (SN) in cancer survivors. However, to date, research on those risks in germinoma survivors is still limited. The aim of this study is to evaluate the impact of GHT in relation to tumor recurrence and development with SN in pure germinoma survivors. Methods This retrospective cohort study was approved by the Ethical Committee for Epidemiology of our institution. Seventy-three consecutive patients who underwent a biopsy of the lesion and were diagnosed with pure germinoma were retrospectively studied. They (median age, 15.0 years) were followed up more than 1 year after biopsy (median follow-up period, 14.3 years). The following data was obtained from the medical records of the patients: age, sex, preoperative magnetic resonance imaging findings, hormonal replacement, and events including tumor recurrence and/or SN. Results In our patient series, 16 patients (21.9%) who were more likely to have neurohypophysial lesion and receive multiple hormonal therapies had received GHT. No significant differences in the rates of tumor recurrence and development with SN were observed between the patients who had and had not received GHT. Moreover, the recurrence-free survival and overall survival rates were not different between the patients who had and had not received GHT. Conclusions GHT did not increase the risks of tumor recurrence and development with SN in pure germinoma survivors.